Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Seizures are further classified into mild seizures and stronger seizures depending on the severity of the seizures. The diagnosis of mild seizures are difficult, as its lasts only for few seconds. Stronger seizures may last for a few seconds to several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Epilepsy occurring due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.
Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/1701
Antiepileptic Drugs Market Drivers
Factors such as rising prevalence of epilepsy and robust pipeline are expected to boost the market growth over the forecast period. According to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally have epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China. Moreover, according to the Centers for Disease Control and Prevention, in 2017, an estimated 3.4 million people have active epilepsy in the U.S., which includes 3 million adults and 470,000 children. Manufacturers have potential drug molecules in the pipeline for the treatment of various forms of epilepsy. For instance, SK Life Sciences, Inc. has Cenobamate (YKP3089) in Phase 3 clinical trials. Eisai, Co., Ltd. has the drug Perampanel in Phase 2 clinical trials, and Marinus Pharmaceuticals, Inc. has the drug Ganaxolone in Phase II clinical trials.
Antiepileptic Drugs Market Regional Analysis
North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast period, owing to drug launches by leading manufacturers in the region. For instance, UCB Pharma received approval in Japan for Vimpat adjunctive therapy for partial onset seizures of epilepsy in 2016. Moreover, Eisai Pharma launched antiepilepsy drug Fycompa in India in 2017.
Antiepileptic Drugs Market Competitive Landscape
Key players operating in the global antiepileptic drugs market include GlaxoSmithKline plc, Johnson & Johnson, Valeant Pharmaceuticals International, Inc., Abbott Laboratories, Cephalon, Inc., Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Novartis AG, UCB Pharma Ltd., and Sanofi S.A.